ARTICLE | Company News
Alectos Therapeutics, Merck deal
August 16, 2010 7:00 AM UTC
Alectos partnered with Merck to discover and develop compounds that modulate O-linked N-acetylglucosaminidase (O-GlcNAcase) for Alzheimer's disease (AD) and other potential disorders. The companies w...